849
Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).
 adult patients (15-60 years old): Subject; adult: Subject.Age; 15-60 years old: Subject.Age; reverse P-glycoprotein-mediated resistance: Effect; quinine: Treatment; quinine: Treatment.Drug; de novo acute myelogenous leukemia (AML): Treatment.Disorder
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 adult patients (15-60 years old): Subject; adult: Subject.Age; 15-60 years old: Subject.Age; reverse P-glycoprotein-mediated resistance: Effect; quinine: Treatment; quinine: Treatment.Drug; de novo acute myelogenous leukemia (AML): Treatment.Disorder